US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.8441 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle ↗
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
News headline image
10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar ↗
The WHO reports that colorectal cancer is the second most fatal cancer around the world. 
Via Benzinga
News headline image
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
From Mainz BioMed NV
Via GlobeNewswire
Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible
--News Direct-- 
Via News Direct
News headline image
Where Mainz Biomed Stands With Analysts ↗
 
Via Benzinga
News headline image
Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech ↗
Colorectal cancer is the third most common cancer worldwide, and although the majority of colorectal cancer cases have historically occurred in individuals aged 45 and older, it is increasingly... 
Via Benzinga
News headline image
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why US Steel Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket ↗
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue. 
Via Benzinga
News headline image
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
Israel has one of the highest screening compliance rates in the world with over one million people being screened each year 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Secures up to $50M in New Funding
Provides option to access capital to support commercial and clinical programs 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Expands Commercial Footprint into Poland
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today 
Via PressReach
Topics Death
News headline image
Being Overweight or Obese Increases Risk of Developing Colorectal Cancer
Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most... 
Via PressReach
News headline image
Mainz Biomed Expands Commercial Footprint into Poland
From Mainz BioMed NV
Via GlobeNewswire
News headline image
BioNTech’s mRNA Vaccine Shows Early Potential Against Pancreatic Cancer
One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system’s defense? One of the deadliest forms of cancer around,... 
Via PressReach
News headline image
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
News headline image
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
News headline image
Colon Cancer Creeping Into Younger Adults – New R&D Uncovers Early Signs
Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are... 
Via PressReach
News headline image
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
From Mainz BioMed NV
Via GlobeNewswire
News headline image
AI Tool Predicts Colon Cancer Survivorship and Response to Treatment
Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options. The new... 
Via PressReach
Topics Artificial Intelligence
News headline image
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
News headline image
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Participate in Digestive Disease Week 2023
Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery 
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >